Affinia Therapeutics, a Waltham, Mass.-based gene therapy company, closed a $60m Series A financing.

Joining the board of directors as part of the financing are Dave Grayzel, M.D., Partner, Atlas Venture; Ed Mathers, General Partner, NEA; and Robert Weisskoff, Ph.D., Partner, F-Prime Capital.

Industry veteran and gene therapy leader Sean Nolan will chair the board.

Led by recently appointed Chief Executive Officer Rick Modi, Affinia Therapeutics operates a proprietary platform that methodically engineers novel AAV vectors and gene therapies that have tissue targeting and other properties.

Its gene therapy products have an initial focus on muscle and central nervous system (CNS) diseases. | To read full story, visit https://startuparound.com/read/1585782108.9183092/Affinia-Therapeutics-Raises-$60M-in-Series-A-Financing?ref=audio_experience